Página 3 - Melhores Câncer ósseo médicos - TOP-71 médicos

Dr. Chaitainya Borde is a nuclear medicine specialist with 12 years of clinical experience. He is skilled in advanced nuclear scans, PET-CT imaging, and nuclear cardiology. He works in both diagnostic and therapeutic nuclear medicine.

Dr. Borde has performed over 30,000 PET scans. He has managed more than 1,000 thyroid cancer patients. He is experienced in radioiodine and Lu-177 RN therapies. He has also published research papers in respected medical journals, showing his dedication to academic work.

Dr. Shruti Kate is an experienced oncologist. She specializes in treating lung, breast, gynecological, and genitourinary cancers. She earned her MBBS from Lady Hardinge Medical College. She completed her MD in Internal Medicine at Maulana Azad Medical College. She also holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai.

Dr. Kate has managed both conservative and surgical cancer treatments. She is skilled in complex procedures such as the Whipple surgery. She is a member of several leading oncology societies, including ASCO, ESMO, IASCLC, ISMPO, and IOS. Her research on lung cancer received the only travel award from India at the 2018 World Conference on Lung Cancer.

Dr. Shaunak Valame is an MD in Internal Medicine and holds a DNB in Medical Oncology. He received advanced training at Indraprastha Apollo Hospital in New Delhi. He also worked as a Registrar at Jawaharlal Nehru Cancer Hospital in Bhopal. Dr. Valame has presented his research at international forums, including the Gastrointestinal Cancer Symposium in San Francisco.

He is known for his work in targeted cancer therapies. He has given lectures at the International Winter School of Oncology at AIIMS Bhopal. Dr. Valame is accredited by the American Society of Clinical Oncology. He is committed to advancing cancer research and clinical care.

Dr. Sridhar P.S. is a skilled radiation oncologist. He earned his Bachelor of Medicine from Mysore University. He completed his MD in Radiotherapy at Banaras Hindu University. He also holds a Diplomate of the National Board in Radiotherapy. This shows his advanced training and dedication to quality care.

Dr. Sridhar is a member of several professional groups. These include the Association of Radiation Oncology of India, Society for Neuro-Oncology, Bangalore Oncology Group, and the Indian Association of Hyperthermia Oncology. He is known for his effective cancer treatments and focus on new therapies. His work has made a positive impact in the field of oncology.

Dr. López-Ibor is a specialist in Pediatric Hematology and Oncology. She earned her medical degree from the Complutense University of Madrid and her doctorate from the University of Barcelona. She is also accredited by the University of Maryland. Dr. López-Ibor treats bone and brain tumors, leukemia, and blood disorders.

She has over 20 years of experience. Dr. López-Ibor leads the Pediatric Hematology and Oncology Unit at HM Montepríncipe Hospital. She has written many scientific articles, both nationally and internationally, and has made important contributions to her field.

Prof. Dr. Osman İLHAN graduated from Ankara University Faculty of Medicine in 1978. After completing his internal medicine residency at the same faculty in 1982, he served as a senior resident at the GATA Hematology Clinic during his military service. After completing his mandatory service at SSK Ulus Hospital, he returned to Ankara University Faculty of Medicine for a subspecialty. In 1990, he became an associate professor of hematology. He worked in Genoa, Italy to increase his knowledge and experience in leukemia. He was part of the team that performed the first bone marrow stem cell transplant in Turkey. In 1996, he went to the MD Anderson Cancer Center in the USA to work on "Stem Cell Mobilization, Cryopreservation, and Transplantation." In 1996, he became a professor of hematology. In 1999, he was elected as the regional president of ESFH (European Society for Hemapheresis). Dr. İlhan, who was the founder and president of the Hemapheresis Society in 2000, joined the World Apheresis Association (WAA) in 2001. He became the President of the Turkish Hematology Association in October 2001. Dr. İlhan, who is an active member of the European Hematology Association (EHA), was a member of the accreditation committee (ECAH) for education. He played a role in the accreditation of Turkish hematologists in CME credits by participating in the accreditation of congresses and courses held in Turkey as a Provider Status. He served as the founding president of the Cellular Therapy and Regenerative Medicine Association established in 2008. He became the founding president of the Geriatric Hematology Association in 2011. He is the Honorary President of the World Apheresis Congress (WAA) held in 2012. Dr. İlhan, who previously served on drug licensing and ethics committees at the Ministry of Health, has also served as the Chairman of the Photopheresis-Apheresis Commission and the Scientific Committee for Bone Marrow Transplantation, as well as the Chairman of the National Organ Tissue Cell Coordination Board, the Scientific Board of Cord Blood, and the Stem Cell Research Board. He is the founding president of the STEM CELL FOUNDATION and has played an important role in the establishment of TURKOK (Turkish Stem Cell Donor Bank). Dr. İlhan has over 300 publications in journals registered in PubMed and more than 5000 citations. He holds the Platinum CME certificate from the European Hematology Association. He owns four brands/patents named “Kökten Çözüm (Deep Solution), Telehematoloji (Telehematology), Hemaferez (Hemapheresis), Kanser Kök Hücresi (Cancer Stem Cell)”. He is currently the President of the Ankara Medical Association. Prof. Dr. Osman İlhan, who served at Ankara University Faculty of Medicine for 50 years, began working at Özel Koru Ankara Hospital as of January 1, 2023.

His medical interests include:

Hematopoietic Stem Cell Transplantation (Autologous, Allogeneic)

Acute Leukemia

Chronic Leukemia Treatments

Hodgkin Lymphoma

Non-Hodgkin Lymphoma Treatments

Multiple Myeloma Treatments, MDS

Aplastic Anemia

ITP

TTP Treatments

Hypercoagulability

Hereditary Thrombophilia Treatments

Therapeutic Apheresis

Photopheresis

Geriatric Hematology Diseases.

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Educação e Formação

1997 a 2003
Universidade de Istambul, Faculdade de Medicina Cerrahpaşa
Istambul, Turquia
Grau: Doutor em Medicina (M.D.)

2003 a 2010
Hospital de Educação e Pesquisa de Taksim
Istambul, Turquia
Residência: Ortopedia e Traumatologia

2010 a 2017
Hospital de Doenças Ósseas Baltalimanı para Educação e Formação
Istambul, Turquia
Posição: Especialista em Ortopedia e Traumatologia

2017 – Presente
Universidade Aydın de Istambul, Faculdade de Medicina
Departamento: Ortopedia e Traumatologia
Posição: Membro do Corpo Docente

Certificação em Ortopedia

2010
Conselho Turco de Ortopedia e Traumatologia
Istambul, Turquia

2014
Conselho Europeu de Ortopedia e Traumatologia (EBOT)

Filiações Nacionais

-Associação Médica Turca

-Sociedade Turca de Cirurgia Ortopédica e Traumatologia

-AO Turquia (Arbeitsgemeinschaft für Osteosynthesefragen)

-FEBOT (Fellow do Conselho Europeu de Ortopedia e Traumatologia)

Publicações em Revistas Internacionais com Revisão por Pares

A.1 Arıkan Y, Yavuz U, Lapcin O, Sökücü S, Özkan B, Kabukçuoğlu Y.
Ablation por radiofrequência percutânea para osteoma osteoide sob orientação de fluoroscopia tridimensional.
J Orthop Surg (Hong Kong). 2016.

A.2 Özcan Ç, Sökücü S, Beng K, Çetinkaya E, Demir B, Kabukçuoğlu YS.
Estudo prospectivo comparativo de dois métodos de fixação após osteotomia corretiva do fêmur distal para deformidade em valgo; encavilhamento intramedular retrógrado versus sistema de estabilização menos invasivo.
Int Orthop. 2016.

A.3 Karakoyun O, Sökücü S, Erol MF, Kucukkaya M, Kabukçuoğlu YS.
Uso de um prego ósseo magnético para alongamento do fêmur e da tíbia.
J Orthop Surg (Hong Kong). 2016.

A.4 Balioğlu MB, Albayrak A, Atıcı Y, Sökücü S, Tacal MT, Kaygusuz MA.
Efeito da ressecção local simples na dor e na curva escoliótica em pacientes com escoliose secundária ao osteoma osteoide e osteoblastoma na coluna vertebral.
Acta Orthop Traumatol Turc. 2016.

A.5 Sökücü S, Aycan OE, Arıkan Y, Kabukçuoğlu YS.
Proliferação osteocondromatosa parosteal bizarra congênita em localização e idade incomuns: relato de caso.
Acta Orthop Traumatol Turc. 2016.

A.6 Bilgili F, Kılıç A, Sökücü S, Parmaksızoğlu A, Çepni K, Kabukçuoğlu Y.
Análise retrospectiva de fraturas de tíbia tipo AO 42A–B tratadas com placa bloqueada percutânea e encavilhamento intramedular.
Ulus Travma Acil Cerrahi Derg. 2016.

A.7 Özcan Ç, Sökücü S, Beng K, Çetinkaya E, Demir B, Kabukçuoğlu Y.
Estudo prospectivo comparativo de dois métodos de fixação após osteotomia corretiva do fêmur distal para deformidade em valgo; encavilhamento intramedular retrógrado versus sistema de estabilização menos invasivo.
Int Orthop. 2016.

A.8 Cetinkaya E, Yalcinkaya M, Sökücü S, Polat A, Ozkaya U, Parmaksizoglu A.
Quilectomia como opção de tratamento cirúrgico de primeira linha fornece bons resultados funcionais no hallux rigidus grau III.
J Am Podiatr Med Assoc. 2016.

A.9 Sökücü S, Menges O, Çetinkaya E, Parmaksızoğlu A, Kabukçuoğlu Y.
Tratamento de fraturas cominutivas da diáfise média da clavícula por fixação com placa usando uma técnica de ponte.
Acta Orthop Traumatol Turc. 2014.

A.10 Sökücü S, Karakoyun O, Arıkan Y, Küçükkaya M, Kabukçuoğlu Y.
Eficácia do quadro espacial Taylor no tratamento de deformidades ao redor do joelho.
Acta Orthop Traumatol Turc. 2013.

A.11 Küçükkaya M, Karakoyun Ö, Sökücü S, Soydan R.
Alongamento femoral e correção de deformidade usando o prego de alongamento motorizado Fitbone.
J Orthop Sci. 2014. 

A.12 Yalcinkaya M, Sökücü S, Erdoğan S, Kabukçuoğlu Y.
Uso de torniquete na cirurgia ortopédica: um estudo descritivo entre cirurgiões ortopédicos turcos e residentes em Istambul.
Acta Orthop Traumatol Turc. 2014.

A.13 Sökücü S, Demir B, Lapcin O, Yavuz U, Kabukçuoğlu Y.
Medida perioperatória versus pós-operatória dos parâmetros de montagem do Quadro Espacial Taylor.
Acta Orthop Traumatol Turc. 2014.

A.14 Yavuz U, Sökücü S, Demir B, Özer D, Özcan Ç, Kabukçuoğlu Y.
Fusão subtalar isolada para fraturas intra-articulares calcâneas negligenciadas e dolorosas.
Acta Orthop Traumatol Turc. 2014.

A.15 Yalcinkaya M, Yavuz U, Sökücü S, Chen C-Y, Lin K-C.
Influência da proeminência do prego e ponto de inserção na dor anterior do joelho após encavilhamento intramedular da tíbia.
Orthopedics. 2014.

A.16 Yavuz U, Sökücü S, Demir B, Yıldırım T, Özcan Ç, Kabukçuoğlu Y.
Comparação da fixação com encavilhamento intramedular ou placa nas fraturas diafisárias distais da tíbia próximas à mortise.
Turk J Trauma Emerg Surg. 2014.

A.17 Karakoyun Ö, Küçükkaya M, Sökücü S.
Distração cinética esquelética intramedular no alongamento dos membros inferiores.
Acta Orthop Traumatol Turc. 2014.

A.18 Gül M, Yavuz U, Sökücü S, Çetinkaya E, Arıkan Y, Kabukçuoğlu Y.
Método de flexão-adução-rotação externa para luxações do ombro.
Acta Orthop Traumatol Turc. 2014.

A.19 Yavuz U, Sökücü S, Demir B, Akpınar E, Lapçin O, Atıcı Y, Kabukçuoğlu Y.
Fratura de estresse incomum em um arqueiro com hipofosfatasia.
Case Reports in Orthopedics. 2013.

A.20 Demir B, Sökücü S, Özden E, Yavuz U, Duman S, Kabukçuoğlu Y.
Nova técnica de aplicação de fixador circular para tratamento de fraturas abertas da tíbia: técnica do fixador circular com dobradiça.
Turk J Trauma Emerg Surg. 2013.

Publicações em Revistas Nacionais com Revisão por Pares 

D.1 Kabukcuoglu Y, Yalcinkaya M, Sokucu S.
Estadiamento e princípios de tratamento cirúrgico em tumores ósseos malignos.
Revista TOTBID. 2014.

D.2 Yavuz U, Sokucu S, Demir B, Yalcinkaya M, Cetinkaya E, Coskun M, Kabukcuoglu Y.
Avaliação da necessidade de radiografias de rotina em pacientes com trauma de tornozelo usando as Regras de Ottawa.
Revista Médica de Göztepe. 2013.

D.3 Yavuz U, Bayhan AI, Atici Y, Sokucu S, Kargin D, Uzun M.
Prevalência de anomalias da coluna lombar detectadas radiograficamente em uma população masculina.
Revista de Cirurgia Espinhal Turca. 2013.

D.4 Beng K, Lapcin O, Sokucu S, Ozkazanli G, Kabukcuoglu YS, Parmaksizoglu AS.
Medições de Distância Àpice Ponta em pacientes com fraturas intertrocantéricas do fêmur tratadas com parafuso dinâmico de quadril de 135° e seu impacto nos resultados.
Revista do Hospital de Treinamento e Pesquisa de Kartal. 2013.

D.5 Atici Y, Albayrak A, Tacal TM, Sokucu S, Beng K, Sari S, Kaygusuz MA.
Técnica de costela protética expansível vertical de titânio (VEPTR) no tratamento da escoliose de início precoce: seu efeito na correção da deformidade espinhal, crescimento espinhal, equilíbrio sagital e coronal, e alinhamento do ombro.
Revista de Cirurgia Espinhal Turca. 2012.

D.6 Gul M, Sokucu S, Kabukcuoglu Y, Kabukcuoglu F, Ozkaya U.
Etiologia rara de eqüinismo: Hemangioma intramuscular (relato de caso).
Boletim Médico do Hospital Sisli Etfal. 2011.

D.7 Kilic A, Gul M, Sokucu S, Parmaksizoglu A, Kabukcuoglu Y.
O papel da artroscopia no diagnóstico e tratamento da dor crônica do punho.
Boletim Médico do Hospital Sisli Etfal. 2009.

D.8 Kilic A, Gul M, Sokucu S, Mutlu H, Kabukcuoglu Y.
Avaliação do tratamento do túnel do carpo usando o Questionário de Satisfação do Paciente (PEM).
Boletim Médico do Hospital Sisli Etfal. 2009.

D.9 Sokucu S, Menges O, Gul M, Kabukcuoglu Y.
Luxação anterior bilateral do ombro desenvolvida após pequeno trauma durante o exercício de Pilates.
Boletim Médico do Hospital Sisli Etfal. 2009.

D.10 Gul M, Ozkaya U, Parmaksizoglu A, Sokucu S, Kabukcuoglu Y.
Relato de caso de cisto ganglionar causando queda do pé.
Boletim Médico do Hospital Sisli Etfal. 2008.

D.11 Ozkaya U, Kabukcuoglu Y, Parmaksizoglu A, Kilic A, Sokucu S, Basilgan S.
Resultados da redução aberta e fixação interna em fraturas calcâneas intra-articulares.
Revista do Hospital de Treinamento e Pesquisa de Kartal. 2007.

D.12 Gul M, Kilic A, Sokucu S, Yeniocak S, Kabukcuoglu Y.
Relato de caso: Luxação do cotovelo ipsilateral com fratura-luxação associada do punho.
Revista do Hospital de Treinamento e Pesquisa de Kartal. 2007.

Associate Professor Dr. Emrah Eraslan graduated from Ankara University Faculty of Medicine in 2005. From 2006 to 2011, he worked as a research assistant in the Department of Internal Medicine at Ankara University Faculty of Medicine and became an internal medicine specialist in 2011. Between 2011 and 2013, he worked as an internal medicine specialist and chief physician at Dr. Nafiz Körez Sincan State Hospital and Palu District State Hospital. From 2013 to 2016, he received medical oncology training at Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital and worked there until 2021. In 2023, he became an associate professor and contributed to his field with his publications throughout his career. He currently serves his patients at Koru Ankara Hospital. His medical interests include:

Breast Cancer

Prostate Cancer

Lung Cancer

Colorectal Cancer

Stomach Cancer

Ovarian Cancer

Assoc. Prof. Gorkem Turkkan started his medical education at Gülhane Military Medical Academy in 2003 and completed it at Zonguldak Karaelmas (Bülent Ecevit) University Faculty of Medicine in 2009. He completed his specialization at Trakya University Faculty of Medicine, Department of Radiation Oncology and became a radiation oncology specialist in 2016.

After completing his compulsory service, he served as a Lecturer and Head of Department at Muğla Sıtkı Koçman University Faculty of Medicine, Department of Radiation Oncology, from May 2019 to February 2021. Meanwhile, between March and June 2020, he worked as a clinical researcher at Maastricht University Faculty of Medicine Department of Radiation Oncology – MAASTRO Clinic (Netherlands) on stereotactic radiotherapy, thoracic radiotherapy-related lung toxicity and proton therapy. While he was working at İstinye University Faculty of Medicine, Department of Radiation Oncology and Liv Hospital Ulus Radiation Oncology Clinic between March 2021 and April 2023, he received the title of Associate Professor in February 2023. She has been serving her patients at Hisar Hospital Intercontinental since May 2023.

He has performed both traditional radiotherapy and advanced radiotherapy throughout his career. He is one of the experienced physicians in our country in stereotactic radiotherapy and MRI-guided radiotherapy treatments, which have become increasingly popular and used especially recently. So far, he has successfully completed more than 2500 radiotherapy sessions with the MR-Linac device.

He has been a member of the Turkish Society of Radiation Oncology (TROD) since 2013 and the European Society of Radiotherapy and Oncology (ESTRO) since 2015. He has 27 articles published in domestic and international journals, 31 oral-poster presentations presented at national and international congresses, and 5 book chapters published by national and international publishing houses. He taught Term I and Term V undergraduate courses at Muğla Sıtkı Koçman University Faculty of Medicine, postgraduate courses within the scope of Ear Nose and Throat Department Specialization training, and Radiotherapy associate degree courses at İstinye University Vocational School of Health Services. She is currently working on 2 ongoing TÜBİTAK Projects. He is married and has a son.

MEDICAL INTERESTS

MR-Linac

Linac

Stereotactic (Pinpoint) Radiotherapy

Prostate Cancers

Breast Cancers

Lung Cancers

Rectum Cancers

Brain and Spinal Cord Cancers

Head and Neck Cancers

Volumetric Arc Therapy (VMAT)

Intensity Modulated Radiotherapy (IMRT)

Head of Teaching at the Puerto Vallarta Regional Hospital

2020-2023

Medical records manager at the Regional Hospital of Puerto Vallarta 2 months 2020

General practitioner in private medical office

2015-2022

Doctor in charge of weight control clinic

2013-2014

Medical assistant in dermatology clinic

2008-2013

Medical Assistant in Dermatological procedures.

 Medical Assistant in minimally invasive surgical procedures

 Operation of fractional laser machine - IPIXEL-ER and

facial rejuvenation with IPL.

 Experience in laser hair removal with Intense Pulsed Light and

radiofrequency

 Experience with ultrasonic cavitation

 Experience with ultraviolet (UV) light phototherapy machine for the

treatment of psoriasis and vitiligo.

 Experience assisting in Botox and Fillers procedures.

 Biomagnet certified by the Higher Institute of Biomagnetism

doctor ISAAC GOIZ DURAN

 Experience in clinical records

 Training in continuing education and professional development of teachers

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

• Education: 
•  
• 2001-2007: University of Ioannina Medical School, Greece.
• 2007: Degree in Medicine.
• 2013: Doctoral degree from the Medical School of the Johann Wolfgang Goethe University, Frankfurt (Dr. Med)
• 09.2016 – Today: Master’s in Healthcare Business Studies.

Professional experience:

04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach

05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach

• 01.2016 – 06.2017: Senior physician in the Department of interventional Radiation Oncology, Medical Center Athens
•  
• 07.2017 – Today: Head of the Department of Radiation Oncology at the German Oncology Center, Limassol, Cyprus.

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)